Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Cryoport, Inc. reported results from its 2026 Annual Meeting of Stockholders. Shareholders elected six directors, with votes for each nominee ranging from 38.9 million to 40.9 million, with additional broker non-votes recorded.
Stockholders ratified Deloitte & Touche LLP as independent auditor with 47,014,962 votes for. They approved executive compensation on an advisory basis with 39,533,693 votes for, and approved an amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares, with 30,110,893 votes for and 12,591,758 against.
Cryoport, Inc. director Linda Baddour received new equity compensation on June 5, 2026. She was granted 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into 10,350 shares of common stock on a one-for-one basis at that time.
She also received options to buy 16,077 shares of common stock at an exercise price of $15.70 per share. One-twelfth of these options vest on the 5th of each month for twelve months beginning July 5, 2026, and they expire on June 5, 2033. Following the restricted stock grant, she directly holds 68,099 common shares.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported an open-market sale of 169,427 shares of Cryoport common stock. The sale occurred on June 4, 2026 at a weighted average price of $16.2724 per share, with individual sale prices ranging from $16.05 to $16.70. Following this transaction, Stefanovich directly owns 109,850 Cryoport common shares.
Cryoport, Inc. director Daniel M. Hancock reported equity awards consisting of restricted stock and stock options. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into the same number of common shares when vested.
He was also granted options to buy 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033. One-twelfth of these options vest monthly on the 5th, starting July 5, 2026. Following the grants, he directly holds 69,052 common shares.
Cryoport, Inc. director Robert J. Hariri reported equity compensation awards. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and then convert one-for-one into common shares.
He was also granted options for 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033, with 1/12 of the options vesting monthly beginning July 5, 2026. Following these awards, he directly holds 61,625 shares of common stock, plus the new option grant.
Cryoport, Inc. director Ramkumar Mandalam reported a mix of equity grants and a stock sale. On June 5, 2026, he received 10,350 restricted stock rights that vest in full on June 5, 2027 and convert one-for-one into common shares, plus options for 16,077 shares at an exercise price of $15.70 expiring in 2033.
On June 8, 2026, he executed an open-market sale of 23,214 common shares at a weighted average price of $15.4412 per share, in multiple trades between $15.40 and $15.48. Following the sale, he directly holds 67,894 common shares.
CYRX submitted a Form 144 notice reporting the proposed sale of 23,214 shares of Common Stock tied to restricted stock vesting under a registered plan. The underlying transaction date is 06/06/2026 and the filing shows broker/dealer Morgan Stanley Smith Barney LLC.
Cryoport, Inc. affiliate submitted a Form 144 reporting proposed sales of Common Stock tied to multiple stock option lots. The filing lists option lots of 47,812, 53,334, 20,000, 16,864, 16,000, 5,000, and 10,417 shares with grant dates ranging from 06/01/2021 to 12/11/2024
The Form 144 is a notice of intended resale by an affiliate under regulatory procedures; the filing lists the securities to be sold but does not state executed transaction proceeds or timing.
Cryoport, Inc. reports Q1 2026 results with total revenue of $47.8 million, up from $41.0 million a year earlier, driven by both services and products. Life Sciences Services contributed $26.9 million and Life Sciences Products $20.9 million.
The company recorded a loss from operations of $9.6 million versus $7.2 million last year, and a net loss of $10.5 million compared with $12.0 million. Net loss attributable to common stockholders was $12.5 million, or $0.25 per share, including a $2.0 million paid‑in‑kind dividend on Series C preferred stock.
Cryoport classified its former CRYOPDP courier business as discontinued operations following its 2025 divestiture and booked a $1.1 million loss from discontinued operations tied to an adjustment on the disposal. The company ended the quarter with $403.6 million in cash, cash equivalents and short‑term investments and generated $3.7 million of operating cash flow, while carrying $186.2 million of 0.75% Convertible Senior Notes due in 2026.